BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1035 related articles for article (PubMed ID: 17959279)

  • 1. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural characterization of archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) formulations prepared by different protocols and their efficacy upon intranasal immunization of mice.
    Patel GB; Ponce A; Zhou H; Chen W
    J Liposome Res; 2008; 18(2):127-43. PubMed ID: 18569448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of intranasally administered archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) vaccine in mice.
    Patel GB; Ponce A; Zhou H; Chen W
    Int J Toxicol; 2008; 27(4):329-39. PubMed ID: 18821397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Archaeal lipid mucosal vaccine adjuvant and delivery system.
    Patel GB; Chen W
    Expert Rev Vaccines; 2010 Apr; 9(4):431-40. PubMed ID: 20370552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
    Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
    Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
    Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
    Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with liposomes induces strong mucosal immune responses in mice.
    Vadolas J; Davies JK; Wright PJ; Strugnell RA
    Eur J Immunol; 1995 Apr; 25(4):969-75. PubMed ID: 7737300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
    Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
    Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.
    Mason KW; Zhu D; Scheuer CA; McMichael JC; Zlotnick GW; Green BA
    Vaccine; 2004 Sep; 22(25-26):3449-56. PubMed ID: 15308371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
    Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
    Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design.
    Bessa J; Schmitz N; Hinton HJ; Schwarz K; Jegerlehner A; Bachmann MF
    Eur J Immunol; 2008 Jan; 38(1):114-26. PubMed ID: 18081037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
    Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
    Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
    Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protollin: a novel adjuvant for intranasal vaccines.
    Jones T; Cyr S; Allard F; Bellerose N; Lowell GH; Burt DS
    Vaccine; 2004 Sep; 22(27-28):3691-7. PubMed ID: 15315848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Archaeosomes with encapsulated antigens for oral vaccine delivery.
    Li Z; Zhang L; Sun W; Ding Q; Hou Y; Xu Y
    Vaccine; 2011 Jul; 29(32):5260-6. PubMed ID: 21609747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposome adjuvants prepared from the total polar lipids of Haloferax volcanii, Planococcus spp. and Bacillus firmus differ in ability to elicit and sustain immune responses.
    Sprott GD; Dicaire CJ; Gurnani K; Deschatelets LA; Krishnan L
    Vaccine; 2004 Jun; 22(17-18):2154-62. PubMed ID: 15149772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model.
    Alcón VL; Baca-Estrada M; Vega-López MA; Willson P; Babiuk LA; Kumar P; Foldvari M
    J Pharm Pharmacol; 2005 Aug; 57(8):955-62. PubMed ID: 16102250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant TNF-alpha, mTNF-K90R, is a novel candidate adjuvant for a mucosal vaccine against HIV.
    Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y
    Pharmazie; 2010 Apr; 65(4):254-6. PubMed ID: 20432620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
    Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
    J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.